Figure 3
Effects of siRNA specific for DPD or TS on sensitivity of UC cells to 5-FU and the antitumor effect of S-1 in UC xenograft model. (A) Expression of DPD mRNA in UMUC-3 cells treated with or without siRNA targeting DPD. Nontargeting control (NTC) siRNA was also used as a negative control. (B) Effects of DPD siRNA on sensitivity of UMUC-3 cells to 5-FU. UMUC-3 cells transfected with siRNA targeting DPD or NTC were treated with various concentrations of 5-FU. The cell viabilities were measured by WST assay. (C) Expression of TS mRNA in UMUC-3 cells treated with or without siRNA targeting TS. (D) Effects of TS siRNA on sensitivity of UMUC-3 cells to 5-FU. UMUC-3 cells transfected with siRNA targeting TS or NTC were treated with various concentrations of 5-FU. A-D, Each value represents the mean derived from at least three individual experiments *, more statistically significant than controls (p < 0.05); bars ± SE. (E) Treatment in vivo. UMUC-3 cells (2 × 106) were implanted s.c. into the flank of nude mice. When a palpable tumor had developed, S-1 (8.3 mg/kg), UFT (20 mg/kg) and tegafur (180 mg/kg) were administered orally once daily. Control animals were administered vehicle alone. Mean tumor volumes in mm3 are shown. E, *, more statistically significant than UFT, tegafur and controls (p < 0.05); bars ± SE.